Home > Nicole Concin, ESMO 2020 – The Launch of the Phase II LIO-1 Trial Investigating Lucitanib plus Nivolumab in Advanced Metastatic Solid Tumours
Gynecological Oncology

Nicole Concin, ESMO 2020 – The Launch of the Phase II LIO-1 Trial Investigating Lucitanib plus Nivolumab in Advanced Metastatic Solid Tumours

Published Online: October 5th 2020
Authors: Nicole Concin

Following the presentation of the phase Ib LIO-1 Dr Nicole Concin provides an overview of the design of the phase II LIO-1 trial and the rationale behind lucitanib plus nivolumab as a potential therapy for solid tumours.The poster ‘LIO-1: A Phase 2 Study of Lucitanib + Nivolumab in Patients (pts) With Gynaecological Tumours’ was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020, and can be found here. The phase Ib LIO-1 poster can be found here.

Questions

  1. What is the rationale behind using a combination of a tyrosine kinase inhibitor plus a monoclonal antibody targeting PD1? (0:23)
  2. What is the mechanism of action of lucitanib plus nivolumab? (2:52)
  3. What do we already know about this combination and how will this inform the phase II LIO-1 trial? (3:37)
  4. What are the aims and design of the phase II LIO-1 trial? (6:14)
  5. What are the future directions for the phase II LIO-1 trial? (9:08)

Speaker Disclosure: Nicole Concin has been an advisor for AstraZeneca, Mersana, and Seattle Genetics; has received travel/accommodation expenses from Amgen, Genmab, and Roche; and has received personal fees and travel expenses from Medscape

Support: Interview and filming supported by Touch Medical Media Ltd. The LIO-1 trial was sponsored by Clovis Oncology, Inc.

Filmed in coverage of the Virtual 2020 ESMO Congress.

 

PD1 = programmed cell death protein 1.

Share this Video
Related Videos In Gynecological Oncology
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar